Like many other cancers, dysregulated kinase activity is a main feature driving AML oncogenic signaling, with the most common mutations seen at diagnosis in the receptor tyrosine kinase FLT3 (20–35% patients) [35, 36]. Here, NTRK1 is linked to acute myeloid leukemia.